| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a7f82940e47ba7a1188f8e2ffca55e0f |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P13-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P15-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-21
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-212 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P13-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P15-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P17-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K33-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-21 |
| filingDate |
1989-10-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bea1e6bb97f3acf701544fa2cbc44dc0
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fbbbb04a6d92283b8d578670666602c3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_df2bf1b081a12c1bbd19ca97c918ce69 |
| publicationDate |
1990-05-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-9004977-A2 |
| titleOfInvention |
Treatment of genital warts with a combination of liquid nitrogen and recombinant dna human alpha interferon |
| abstract |
Condylomata acuminata infections (anogenital warts) are treated in infected patients by use of a combined therapy, i.e. by administering liquid nitrogen and immediately thereafter beginning administering recombinant DNA human alpha interferon thrice a week for three weeks. The pharmaceutical composition of interferon for use in the combined therapy contains recombinant DNA human interferon alfa-2b in which 1.0 x 106 International Units are administered by injection to each lesion. The liquid nitrogen is the cryosurgical agent exemplified and it is topically administered to each lesion by conventional means. The use of human alpha interferon for the manufacture of a medicament for use in the combined therapy exemplified is also disclosed. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-4019037-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2018178215-A1 |
| priorityDate |
1988-11-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |